The following is a summary of “Chronic graft-versus-host disease myelitis successfully treated with rituximab,” published in ...

rituximab might also inhibit T-cell activation. A synergistic effect has been noted in vitro following administration of corticosteroids to B-cell lines, with accentuation of B-cell cytotoxicity ...

Patients were randomised to receive Calquence with chemotherapy bendamustine and Biogen and Genentech’s Rituxan (rituximab) or placebo plus ... "AstraZeneca secures first BTK approval in first-line ...

Moreover, the cells demonstrated improved growth and, compared to similarly treated controls, produced significantly higher yields of protein-based drugs such as Herceptin and Rituximab ...

Moreover, the cells demonstrated improved growth and, compared to similarly treated controls, produced significantly higher yields of protein-based drugs such as Herceptin and Rituximab ...

On average, patients had already received four lines of therapy ... CAR-T cell therapy who then received CAR-NK cell therapy plus rituximab, 45% responded with 30% achieving complete remission.

These participants were randomly assigned to receive the study drug plus the bendamustine/rituximab ... regimen as a first-line treatment for older patients with mantle cell lymphoma.” ...

Depleting B cells with targeted antibodies such as rituximab (anti-CD20 mAb ... it the world’s first anti-PD-1 mAb for the first-line treatment of SCLC. What’s more, Henlius has conducted ...